The most common toxicity associated with TAS-102 was neutropenia, with grade 3 events occurring in 73.3% of patients with colorectal cancer.
Nicholas James Hornstein, MD, PhD
Advertisement
Articles by Nicholas James Hornstein, MD, PhD
“…I like TAS-102 as an agent, but we need better drugs than we have right now to clear ctDNA and cure patients,” said Hornstein, MD, PhD.
The phase 2 INTERCEPT-TT trial showed that TAS-102 induced ctDNA clearance following adjuvant chemotherapy in patients with colorectal cancer.
A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.
The CHALLENGE trial in CRC studied structured exercise and demonstrated a DFS benefit comparable to or exceeding oxaliplatin chemotherapy.
Advertisement
Latest Updated Articles
The CHALLENGE Trial Helps Redefine Adjuvant Therapy With Exercise in CRCPublished: July 6th 2025 | Updated: July 2nd 2025
Best Practices for the Medical Oncology BoardsPublished: July 7th 2025 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Brachytherapy/Vitrectomy, Silicone Oil Confer Positive Uveal Melanoma DMFS
2
Future of Clear Cell Renal Cell Carcinoma
3
How Effective, Safe is Mosunetuzumab/Polatuzumab Vedotin in Pretreated MCL?
4
Overcoming the “Nihilism” Surrounding the Small Cell Lung Cancer Prognosis
5
